Streetbeat News

HLN

Haleon plc

https://www.haleon.com

Industry

Drug Manufacturers - Specialty & Generic

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.

Open

9.42

Mkt cap

43B

Volume

High

9.50

P/E Ratio

28.74

52-wk high

10.80

Low

9.40

Div yield

0.02

52-wk low

7.89

Haleon has reiterated its FY24 organic revenue growth forecast of 4%-6% and expects high-single digit growth in organic operating profit. The company is confident in delivering on its medium-term guidance.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 8:12 am

Haleon reported H1 sales of $7.231 billion, missing the estimated $8.641 billion.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 8:08 am

Haleon plc (NYSE:HLN) has agreed to sell its nicotine replacement therapy business outside of the U.S. to Dr. Reddy's Laboratories SA, a subsidiary of Dr. Reddy's Laboratories Limited (NYSE:RDY), for approximately $632 million. The transaction is expected to be completed in early Q4 2024 and will allow Haleon to focus on strategic growth areas. The divestment is expected to dilute Haleon's fiscal year 2024 net revenue and adjusted operating profit by around 0.5% and 1%, respectively.

Portfolio Pulse from Vandana Singh

June 26, 2024 | 3:52 pm

Haleon has agreed to sell its nicotine replacement therapy business outside of the U.S. to Dr. Reddy's Laboratories for £500 million.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 3:34 pm

Dr. Reddy's Laboratories Ltd. (NYSE: RDY) is set to acquire Haleon plc's (NYSE: HLN) global portfolio of consumer healthcare brands in the Nicotine Replacement Therapy (NRT) category outside of the United States. The acquisition includes brands like Nicotinell, Nicabate, Thrive, and Habitrol, and covers various formats such as lozenge, patch, gum, and pipeline products.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 3:29 pm

Sanofi SA (NASDAQ:SNY) is seeking bids for its $20 billion consumer health division, which includes products like Icy Hot. Potential buyers include Advent, PAI Partners, Blackstone Inc (NYSE:BX), and others. Sanofi may retain a minority stake post-sale. This move aligns with industry peers like GSK Plc (NYSE:GSK) and Johnson & Johnson (NYSE:JNJ), who have also divested their consumer divisions.

Portfolio Pulse from Vandana Singh

June 26, 2024 | 1:16 pm

GSK plc (NYSE:GSK) has sold its remaining 4.2% stake in Haleon plc (NYSE:HLN) for $1.58 billion, fully exiting its position. This follows a series of disposals since Haleon's demerger and premium listing in July 2022. Pfizer Inc (NYSE:PFE) also plans to reduce its stake in Haleon to approximately 24%.

Portfolio Pulse from Vandana Singh

May 17, 2024 | 2:45 pm

GSK has announced its intention to sell approximately 385 million shares in Haleon. This move is likely to impact both GSK and Haleon in the short term.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 3:44 pm

Haleon reported its Q1 2024 GAAP EPS at £9.20, surpassing the £8.85 estimate. However, its sales of £2.919B fell short of the £2.963B estimate.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 9:25 am

Haleon announced the appointment of Dawn Allen as its new CFO, effective from November 1, following Tobias Hestler's decision to step down. Allen will join the company on October 28.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 9:08 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.